Abstract：
OBJECTIVE: This Bayesian network meta-analysis was performed to analyze the associations between clinicopathological characteristics and BRAF mutations in ameloblastoma (AM) patients and to evaluate the diagnostic accuracy.
METHODS: Four electronic databases were searched from 2010 to 2024. The search terms used were specific to BRAF and AM. Observational studies or randomized controlled trials were considered eligible. The incidence of BRAF mutation and corresponding clinicopathological features in AM patients were subjected to Bayesian network analyses and diagnostic accuracy evaluation.
RESULTS: A total of 937 AM patients from 20 studies were included. The pooled prevalence of BRAF mutations in AM patients was 72%. According to the Bayesian network analysis, BRAF mutations are more likely to occur in younger (odds ratio [OR], 2.3; credible interval [CrI]: 1.2-4.5), mandible site (OR, 3.6; 95% CrI: 2.7-5.2), and unicystic (OR, 1.6; 95% CrI: 1.1-2.4) AM patients. Similarly, higher diagnostic accuracy was found in the younger, mandible, and unicystic AM groups.
CONCLUSIONS: The incidence, risk, and diagnostic accuracy of BRAF mutation in AM were greater in younger patients, those with mandible involvement, and those with unicystic AM than in patients with other clinicopathological features. In addition, there was a strong concordance in the diagnostic accuracy between molecular tests and immunohistochemical analysis.
METHODS: Four electronic databases were searched from 2010 to 2024. The search terms used were specific to BRAF and AM. Observational studies or randomized controlled trials were considered eligible. The incidence of BRAF mutation and corresponding clinicopathological features in AM patients were subjected to Bayesian network analyses and diagnostic accuracy evaluation.
RESULTS: A total of 937 AM patients from 20 studies were included. The pooled prevalence of BRAF mutations in AM patients was 72%. According to the Bayesian network analysis, BRAF mutations are more likely to occur in younger (odds ratio [OR], 2.3; credible interval [CrI]: 1.2-4.5), mandible site (OR, 3.6; 95% CrI: 2.7-5.2), and unicystic (OR, 1.6; 95% CrI: 1.1-2.4) AM patients. Similarly, higher diagnostic accuracy was found in the younger, mandible, and unicystic AM groups.
CONCLUSIONS: The incidence, risk, and diagnostic accuracy of BRAF mutation in AM were greater in younger patients, those with mandible involvement, and those with unicystic AM than in patients with other clinicopathological features. In addition, there was a strong concordance in the diagnostic accuracy between molecular tests and immunohistochemical analysis.
摘要：
目的：这项贝叶斯网络荟萃分析旨在分析成釉细胞瘤（AM）患者的临床病理特征与BRAF突变之间的关联，并评估诊断准确性。
方法：从2010年至2024年检索了四个电子数据库。使用的搜索词特定于BRAF和AM。观察性研究或随机对照试验被认为是合格的。对AM患者BRAF基因突变的发生率及相应的临床病理特征进行贝叶斯网络分析和诊断准确性评价。
结果：共纳入20项研究的937名AM患者。AM患者BRAF突变的合并患病率为72%。根据贝叶斯网络分析,BRAF突变更有可能发生在年轻人中(比值比[OR]，2.3；可信区间[CrI]：1.2-4.5)，下颌骨部位(或，3.6;95%CrI:2.7-5.2),和独症(或者，1.6；95%CrI：1.1-2.4）AM患者。同样，在年轻人中发现了更高的诊断准确性，下颌骨,和单纯性AM组。
结论：发病率，风险，在年轻患者中，AM中BRAF突变的诊断准确性更高，那些有下颌骨参与的人，与单囊AM患者相比，其他临床病理特征患者。此外,分子检测和免疫组织化学分析在诊断准确性上有很强的一致性.
方法：从2010年至2024年检索了四个电子数据库。使用的搜索词特定于BRAF和AM。观察性研究或随机对照试验被认为是合格的。对AM患者BRAF基因突变的发生率及相应的临床病理特征进行贝叶斯网络分析和诊断准确性评价。
结果：共纳入20项研究的937名AM患者。AM患者BRAF突变的合并患病率为72%。根据贝叶斯网络分析,BRAF突变更有可能发生在年轻人中(比值比[OR]，2.3；可信区间[CrI]：1.2-4.5)，下颌骨部位(或，3.6;95%CrI:2.7-5.2),和独症(或者，1.6；95%CrI：1.1-2.4）AM患者。同样，在年轻人中发现了更高的诊断准确性，下颌骨,和单纯性AM组。
结论：发病率，风险，在年轻患者中，AM中BRAF突变的诊断准确性更高，那些有下颌骨参与的人，与单囊AM患者相比，其他临床病理特征患者。此外,分子检测和免疫组织化学分析在诊断准确性上有很强的一致性.
